Industry Research Reports
Home > Reports > Medical Devices & Consumables > Global Autologous Biologics Market Outlook, In‑Depth Analysis & Forecast to 2031
Global Autologous Biologics Market Outlook, In‑Depth Analysis & Forecast to 2031
Industry: Medical Devices & Consumables
Published Date: 2025-11-02
Pages: 131 Pages
Report ld: 5342983
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
The global Autologous Biologics market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
From a downstream perspective, Hospitals accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Autologous Biologics leading manufacturers including Vericel Corporation, BioTime, Inc., Pharmicell Co., BrainStorm Cell Therapeutics, Opexa Therapeutics, Inc, Pharmicell Co., Inc, Neostem, Dendreon Corporation, Regenexx, Cytori Therapeutics, etc., dominate supply; the top five capture approximately % of global revenue, with Vericel Corporation leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).
Report Includes:
This definitive report equips business leaders, decision-makers and stakeholders with a 360° view of the global Autologous Biologics market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region's dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
MARKET SEGMENTATION
By Company
- Vericel Corporation
- BioTime, Inc.
- Pharmicell Co.
- BrainStorm Cell Therapeutics
- Opexa Therapeutics, Inc
- Pharmicell Co., Inc
- Neostem
- Dendreon Corporation
- Regenexx
- Cytori Therapeutics
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- Adipose Tissue
- Plasma
- Others
Segment by Application
- Hospitals
- Ambulatory Centers
- Research Centers
CHAPTER OUTLINE
Chapter 1: Defines the Autologous Biologics study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; top manufactures 2024 sales breakdowns by product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
WHY THIS REPORT
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Study Coverage
1.1 Introduction to Autologous Biologics: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Autologous Biologics Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Adipose Tissue
1.2.3 Plasma
1.2.4 Others
1.3 Market Segmentation by Application
1.3.1 Global Autologous Biologics Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Ambulatory Centers
1.3.4 Research Centers
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Autologous Biologics Revenue Estimates and Forecasts 2020-2031
2.2 Global Autologous Biologics Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Autologous Biologics Sales Estimates and Forecasts 2020-2031
2.4 Global Autologous Biologics Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Autologous Biologics Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Autologous Biologics Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Adipose Tissue Market Size by Manufacturers
3.5.2 Plasma Market Size by Manufacturers
3.5.3 Others Market Size by Manufacturers
3.6 Global Autologous Biologics Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Autologous Biologics Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Autologous Biologics Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Autologous Biologics Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Autologous Biologics Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Autologous Biologics Sales and Revenue by Type (2020-2031)
6.4 North America Autologous Biologics Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Autologous Biologics Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Autologous Biologics Sales and Revenue by Type (2020-2031)
7.4 Europe Autologous Biologics Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Autologous Biologics Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Autologous Biologics Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Autologous Biologics Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Autologous Biologics Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Autologous Biologics Sales and Revenue by Type (2020-2031)
9.4 Central and South America Autologous Biologics Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Autologous Biologics Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Autologous Biologics Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Autologous Biologics Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Autologous Biologics Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Vericel Corporation
11.1.1 Vericel Corporation Corporation Information
11.1.2 Vericel Corporation Business Overview
11.1.3 Vericel Corporation Autologous Biologics Product Models, Descriptions and Specifications
11.1.4 Vericel Corporation Autologous Biologics Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Vericel Corporation Autologous Biologics Sales by Product in 2024
11.1.6 Vericel Corporation Autologous Biologics Sales by Application in 2024
11.1.7 Vericel Corporation Autologous Biologics Sales by Geographic Area in 2024
11.1.8 Vericel Corporation Autologous Biologics SWOT Analysis
11.1.9 Vericel Corporation Recent Developments
11.2 BioTime, Inc.
11.2.1 BioTime, Inc. Corporation Information
11.2.2 BioTime, Inc. Business Overview
11.2.3 BioTime, Inc. Autologous Biologics Product Models, Descriptions and Specifications
11.2.4 BioTime, Inc. Autologous Biologics Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 BioTime, Inc. Autologous Biologics Sales by Product in 2024
11.2.6 BioTime, Inc. Autologous Biologics Sales by Application in 2024
11.2.7 BioTime, Inc. Autologous Biologics Sales by Geographic Area in 2024
11.2.8 BioTime, Inc. Autologous Biologics SWOT Analysis
11.2.9 BioTime, Inc. Recent Developments
11.3 Pharmicell Co.
11.3.1 Pharmicell Co. Corporation Information
11.3.2 Pharmicell Co. Business Overview
11.3.3 Pharmicell Co. Autologous Biologics Product Models, Descriptions and Specifications
11.3.4 Pharmicell Co. Autologous Biologics Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Pharmicell Co. Autologous Biologics Sales by Product in 2024
11.3.6 Pharmicell Co. Autologous Biologics Sales by Application in 2024
11.3.7 Pharmicell Co. Autologous Biologics Sales by Geographic Area in 2024
11.3.8 Pharmicell Co. Autologous Biologics SWOT Analysis
11.3.9 Pharmicell Co. Recent Developments
11.4 BrainStorm Cell Therapeutics
11.4.1 BrainStorm Cell Therapeutics Corporation Information
11.4.2 BrainStorm Cell Therapeutics Business Overview
11.4.3 BrainStorm Cell Therapeutics Autologous Biologics Product Models, Descriptions and Specifications
11.4.4 BrainStorm Cell Therapeutics Autologous Biologics Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 BrainStorm Cell Therapeutics Autologous Biologics Sales by Product in 2024
11.4.6 BrainStorm Cell Therapeutics Autologous Biologics Sales by Application in 2024
11.4.7 BrainStorm Cell Therapeutics Autologous Biologics Sales by Geographic Area in 2024
11.4.8 BrainStorm Cell Therapeutics Autologous Biologics SWOT Analysis
11.4.9 BrainStorm Cell Therapeutics Recent Developments
11.5 Opexa Therapeutics, Inc
11.5.1 Opexa Therapeutics, Inc Corporation Information
11.5.2 Opexa Therapeutics, Inc Business Overview
11.5.3 Opexa Therapeutics, Inc Autologous Biologics Product Models, Descriptions and Specifications
11.5.4 Opexa Therapeutics, Inc Autologous Biologics Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Opexa Therapeutics, Inc Autologous Biologics Sales by Product in 2024
11.5.6 Opexa Therapeutics, Inc Autologous Biologics Sales by Application in 2024
11.5.7 Opexa Therapeutics, Inc Autologous Biologics Sales by Geographic Area in 2024
11.5.8 Opexa Therapeutics, Inc Autologous Biologics SWOT Analysis
11.5.9 Opexa Therapeutics, Inc Recent Developments
11.6 Pharmicell Co., Inc
11.6.1 Pharmicell Co., Inc Corporation Information
11.6.2 Pharmicell Co., Inc Business Overview
11.6.3 Pharmicell Co., Inc Autologous Biologics Product Models, Descriptions and Specifications
11.6.4 Pharmicell Co., Inc Autologous Biologics Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Pharmicell Co., Inc Recent Developments
11.7 Neostem
11.7.1 Neostem Corporation Information
11.7.2 Neostem Business Overview
11.7.3 Neostem Autologous Biologics Product Models, Descriptions and Specifications
11.7.4 Neostem Autologous Biologics Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Neostem Recent Developments
11.8 Dendreon Corporation
11.8.1 Dendreon Corporation Corporation Information
11.8.2 Dendreon Corporation Business Overview
11.8.3 Dendreon Corporation Autologous Biologics Product Models, Descriptions and Specifications
11.8.4 Dendreon Corporation Autologous Biologics Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Dendreon Corporation Recent Developments
11.9 Regenexx
11.9.1 Regenexx Corporation Information
11.9.2 Regenexx Business Overview
11.9.3 Regenexx Autologous Biologics Product Models, Descriptions and Specifications
11.9.4 Regenexx Autologous Biologics Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 Regenexx Recent Developments
11.10 Cytori Therapeutics
11.10.1 Cytori Therapeutics Corporation Information
11.10.2 Cytori Therapeutics Business Overview
11.10.3 Cytori Therapeutics Autologous Biologics Product Models, Descriptions and Specifications
11.10.4 Cytori Therapeutics Autologous Biologics Sales, Price, Revenue and Gross Margin (2020-2025)
11.10.5 Cytori Therapeutics Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Autologous Biologics Industry Chain
12.2 Autologous Biologics Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Autologous Biologics Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Autologous Biologics Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Autologous Biologics Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Autologous Biologics Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
TABLE OF FIGURES
List of Tables
Table 1. Global Autologous Biologics Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Autologous Biologics Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Autologous Biologics Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Autologous Biologics Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Autologous Biologics Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Autologous Biologics Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (Kg)
Table 7. Global Autologous Biologics Sales by Region (2020-2025) & (Kg)
Table 8. Global Autologous Biologics Sales by Region (2026-2031) & (Kg)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Autologous Biologics Sales by Manufacturers (2020-2025) & (Kg)
Table 11. Global Autologous Biologics Sales Share by Manufacturers (2020-2025)
Table 12. Global Autologous Biologics Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Autologous Biologics Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Autologous Biologics by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Autologous Biologics as of 2024)
Table 16. Global Autologous Biologics Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Autologous Biologics Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Kg)
Table 18. Key Manufacturers Autologous Biologics Manufacturing Base and Headquarters
Table 19. Global Autologous Biologics Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Autologous Biologics Sales by Type (2020-2025) & (Kg)
Table 23. Global Autologous Biologics Sales by Type (2026-2031) & (Kg)
Table 24. Global Autologous Biologics Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Autologous Biologics Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Autologous Biologics ASP by Type (2020-2031) & (US$/Kg)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Autologous Biologics Sales by Application (2020-2025) & (Kg)
Table 29. Global Autologous Biologics Sales by Application (2026-2031) & (Kg)
Table 30. Autologous Biologics High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Autologous Biologics Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Autologous Biologics Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Autologous Biologics ASP by Application (2020-2031) & (US$/Kg)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Autologous Biologics Growth Accelerators and Market Barriers
Table 37. North America Autologous Biologics Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Autologous Biologics Sales (Kg) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Autologous Biologics Growth Accelerators and Market Barriers
Table 40. Europe Autologous Biologics Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Autologous Biologics Sales (Kg) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Autologous Biologics Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Autologous Biologics Sales (Kg) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Autologous Biologics Growth Accelerators and Market Barriers
Table 45. Southeast Asia Autologous Biologics Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Autologous Biologics Investment Opportunities and Key Challenges
Table 47. Central and South America Autologous Biologics Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Autologous Biologics Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Autologous Biologics Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Vericel Corporation Corporation Information
Table 51. Vericel Corporation Description and Major Businesses
Table 52. Vericel Corporation Product Models, Descriptions and Specifications
Table 53. Vericel Corporation Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 54. Vericel Corporation Sales Value Proportion by Product in 2024
Table 55. Vericel Corporation Sales Value Proportion by Application in 2024
Table 56. Vericel Corporation Sales Value Proportion by Geographic Area in 2024
Table 57. Vericel Corporation Autologous Biologics SWOT Analysis
Table 58. Vericel Corporation Recent Developments
Table 59. BioTime, Inc. Corporation Information
Table 60. BioTime, Inc. Description and Major Businesses
Table 61. BioTime, Inc. Product Models, Descriptions and Specifications
Table 62. BioTime, Inc. Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 63. BioTime, Inc. Sales Value Proportion by Product in 2024
Table 64. BioTime, Inc. Sales Value Proportion by Application in 2024
Table 65. BioTime, Inc. Sales Value Proportion by Geographic Area in 2024
Table 66. BioTime, Inc. Autologous Biologics SWOT Analysis
Table 67. BioTime, Inc. Recent Developments
Table 68. Pharmicell Co. Corporation Information
Table 69. Pharmicell Co. Description and Major Businesses
Table 70. Pharmicell Co. Product Models, Descriptions and Specifications
Table 71. Pharmicell Co. Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 72. Pharmicell Co. Sales Value Proportion by Product in 2024
Table 73. Pharmicell Co. Sales Value Proportion by Application in 2024
Table 74. Pharmicell Co. Sales Value Proportion by Geographic Area in 2024
Table 75. Pharmicell Co. Autologous Biologics SWOT Analysis
Table 76. Pharmicell Co. Recent Developments
Table 77. BrainStorm Cell Therapeutics Corporation Information
Table 78. BrainStorm Cell Therapeutics Description and Major Businesses
Table 79. BrainStorm Cell Therapeutics Product Models, Descriptions and Specifications
Table 80. BrainStorm Cell Therapeutics Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 81. BrainStorm Cell Therapeutics Sales Value Proportion by Product in 2024
Table 82. BrainStorm Cell Therapeutics Sales Value Proportion by Application in 2024
Table 83. BrainStorm Cell Therapeutics Sales Value Proportion by Geographic Area in 2024
Table 84. BrainStorm Cell Therapeutics Autologous Biologics SWOT Analysis
Table 85. BrainStorm Cell Therapeutics Recent Developments
Table 86. Opexa Therapeutics, Inc Corporation Information
Table 87. Opexa Therapeutics, Inc Description and Major Businesses
Table 88. Opexa Therapeutics, Inc Product Models, Descriptions and Specifications
Table 89. Opexa Therapeutics, Inc Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 90. Opexa Therapeutics, Inc Sales Value Proportion by Product in 2024
Table 91. Opexa Therapeutics, Inc Sales Value Proportion by Application in 2024
Table 92. Opexa Therapeutics, Inc Sales Value Proportion by Geographic Area in 2024
Table 93. Opexa Therapeutics, Inc Autologous Biologics SWOT Analysis
Table 94. Opexa Therapeutics, Inc Recent Developments
Table 95. Pharmicell Co., Inc Corporation Information
Table 96. Pharmicell Co., Inc Description and Major Businesses
Table 97. Pharmicell Co., Inc Product Models, Descriptions and Specifications
Table 98. Pharmicell Co., Inc Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 99. Pharmicell Co., Inc Recent Developments
Table 100. Neostem Corporation Information
Table 101. Neostem Description and Major Businesses
Table 102. Neostem Product Models, Descriptions and Specifications
Table 103. Neostem Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 104. Neostem Recent Developments
Table 105. Dendreon Corporation Corporation Information
Table 106. Dendreon Corporation Description and Major Businesses
Table 107. Dendreon Corporation Product Models, Descriptions and Specifications
Table 108. Dendreon Corporation Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 109. Dendreon Corporation Recent Developments
Table 110. Regenexx Corporation Information
Table 111. Regenexx Description and Major Businesses
Table 112. Regenexx Product Models, Descriptions and Specifications
Table 113. Regenexx Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 114. Regenexx Recent Developments
Table 115. Cytori Therapeutics Corporation Information
Table 116. Cytori Therapeutics Description and Major Businesses
Table 117. Cytori Therapeutics Product Models, Descriptions and Specifications
Table 118. Cytori Therapeutics Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 119. Cytori Therapeutics Recent Developments
Table 120. Key Raw Materials Distribution
Table 121. Raw Materials Key Suppliers
Table 122. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 123. Milestones in Production Technology Evolution
Table 124. Distributors List
Table 125. Market Trends and Market Evolution
Table 126. Market Drivers and Opportunities
Table 127. Market Challenges, Risks, and Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
List of Figures
Figure 1. Autologous Biologics Product Picture
Figure 2. Global Autologous Biologics Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Adipose Tissue Product Picture
Figure 4. Plasma Product Picture
Figure 5. Others Product Picture
Figure 6. Global Autologous Biologics Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 7. Hospitals
Figure 8. Ambulatory Centers
Figure 9. Research Centers
Figure 10. Autologous Biologics Report Years Considered
Figure 11. Global Autologous Biologics Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global Autologous Biologics Revenue (2020-2031) & (US$ Million)
Figure 13. Global Autologous Biologics Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 14. Global Autologous Biologics Revenue Market Share by Region (2020-2031)
Figure 15. Global Autologous Biologics Sales (2020-2031) & (Kg)
Figure 16. Global Autologous Biologics Sales (CAGR) by Region (2020-2031) (Kg)
Figure 17. Global Autologous Biologics Sales Market Share by Region (2020-2031)
Figure 18. Top 5 and Top 10 Manufacturers Autologous Biologics Sales Volume Market Share in 2024
Figure 19. Global Autologous Biologics Revenue Market Share Ranking (2024)
Figure 20. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 21. Adipose Tissue Revenue Market Share by Manufacturer in 2024
Figure 22. Plasma Revenue Market Share by Manufacturer in 2024
Figure 23. Others Revenue Market Share by Manufacturer in 2024
Figure 24. Global Autologous Biologics Sales Market Share by Type (2020-2031)
Figure 25. Global Autologous Biologics Revenue Market Share by Type (2020-2031)
Figure 26. Global Autologous Biologics Sales Market Share by Application (2020-2031)
Figure 27. Global Autologous Biologics Revenue Market Share by Application (2020-2031)
Figure 28. North America Autologous Biologics Sales YoY (2020-2031) & (Kg)
Figure 29. North America Autologous Biologics Revenue YoY (2020-2031) & (US$ Million)
Figure 30. North America Top 5 Manufacturers Autologous Biologics Sales Revenue (US$ Million) in 2024
Figure 31. North America Autologous Biologics Sales Volume (Kg) by Type (2020- 2031)
Figure 32. North America Autologous Biologics Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 33. North America Autologous Biologics Sales Volume (Kg) by Application (2020-2031)
Figure 34. North America Autologous Biologics Sales Revenue (US$ Million) by Application (2020-2031)
Figure 35. US Autologous Biologics Revenue (2020-2031) & (US$ Million)
Figure 36. Canada Autologous Biologics Revenue (2020-2031) & (US$ Million)
Figure 37. Mexico Autologous Biologics Revenue (2020-2031) & (US$ Million)
Figure 38. Europe Autologous Biologics Sales YoY (2020-2031) & (Kg)
Figure 39. Europe Autologous Biologics Revenue YoY (2020-2031) & (US$ Million)
Figure 40. Europe Top 5 Manufacturers Autologous Biologics Sales Revenue (US$ Million) in 2024
Figure 41. Europe Autologous Biologics Sales Volume (Kg) by Type (2020-2031)
Figure 42. Europe Autologous Biologics Sales Revenue (US$ Million) by Type (2020-2031)
Figure 43. Europe Autologous Biologics Sales Volume (Kg) by Application (2020-2031)
Figure 44. Europe Autologous Biologics Sales Revenue (US$ Million) by Application (2020-2031)
Figure 45. Germany Autologous Biologics Revenue (2020-2031) & (US$ Million)
Figure 46. France Autologous Biologics Revenue (2020-2031) & (US$ Million)
Figure 47. U.K. Autologous Biologics Revenue (2020-2031) & (US$ Million)
Figure 48. Italy Autologous Biologics Revenue (2020-2031) & (US$ Million)
Figure 49. Russia Autologous Biologics Revenue (2020-2031) & (US$ Million)
Figure 50. Asia-Pacific Autologous Biologics Sales YoY (2020-2031) & (Kg)
Figure 51. Asia-Pacific Autologous Biologics Revenue YoY (2020-2031) & (US$ Million)
Figure 52. Asia-Pacific Top 8 Manufacturers Autologous Biologics Sales Revenue (US$ Million) in 2024
Figure 53. Asia-Pacific Autologous Biologics Sales Volume (Kg) by Type (2020- 2031)
Figure 54. Asia-Pacific Autologous Biologics Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 55. Asia-Pacific Autologous Biologics Sales Volume (Kg) by Application (2020-2031)
Figure 56. Asia-Pacific Autologous Biologics Sales Revenue (US$ Million) by Application (2020-2031)
Figure 57. Indonesia Autologous Biologics Revenue (2020-2031) & (US$ Million)
Figure 58. Japan Autologous Biologics Revenue (2020-2031) & (US$ Million)
Figure 59. South Korea Autologous Biologics Revenue (2020-2031) & (US$ Million)
Figure 60. China Taiwan Autologous Biologics Revenue (2020-2031) & (US$ Million)
Figure 61. India Autologous Biologics Revenue (2020-2031) & (US$ Million)
Figure 62. Central and South America Autologous Biologics Sales YoY (2020-2031) & (Kg)
Figure 63. Central and South America Autologous Biologics Revenue YoY (2020-2031) & (US$ Million)
Figure 64. Central and South America Top 5 Manufacturers Autologous Biologics Sales Revenue (US$ Million) in 2024
Figure 65. Central and South America Autologous Biologics Sales Volume (Kg) by Type (2021-2031)
Figure 66. Central and South America Autologous Biologics Sales Revenue (US$ Million) by Type (2020-2031)
Figure 67. Central and South America Autologous Biologics Sales Volume (Kg) by Application (2020-2031)
Figure 68. Central and South America Autologous Biologics Sales Revenue (US$ Million) by Application (2020-2031)
Figure 69. Brazil Autologous Biologics Revenue (2020-2025) & (US$ Million)
Figure 70. Argentina Autologous Biologics Revenue (2020-2025) & (US$ Million)
Figure 71. Middle East, and Africa Autologous Biologics Sales YoY (2020-2031) & (Kg)
Figure 72. Middle East and Africa Autologous Biologics Revenue YoY (2020-2031) & (US$ Million)
Figure 73. Middle East and Africa Top 5 Manufacturers Autologous Biologics Sales Revenue (US$ Million) in 2024
Figure 74. Middle East and Africa Autologous Biologics Sales Volume (Kg) by Type (2021-2031)
Figure 75. South America Autologous Biologics Sales Revenue (US$ Million) by Type (2020-2031)
Figure 76. Middle East and Africa Autologous Biologics Sales Volume (Kg) by Application (2020-2031)
Figure 77. Middle East and Africa Autologous Biologics Sales Revenue (US$ Million) by Application (2020-2031)
Figure 78. GCC Countries Autologous Biologics Revenue (2020-2025) & (US$ Million)
Figure 79. Turkey Autologous Biologics Revenue (2020-2025) & (US$ Million)
Figure 80. Egypt Autologous Biologics Revenue (2020-2025) & (US$ Million)
Figure 81. South Africa Autologous Biologics Revenue (2020-2025) & (US$ Million)
Figure 82. Autologous Biologics Industry Chain Mapping
Figure 83. Regional Autologous Biologics Manufacturing Base Distribution (%)
Figure 84. Global Autologous Biologics Production Market Share by Region (2020-2031)
Figure 85. Autologous Biologics Production Process
Figure 86. Regional Autologous Biologics Production Cost Structure
Figure 87. Channels of Distribution (Direct Vs Distribution)
Figure 88. Bottom-up and Top-down Approaches for This Report
Figure 89. Data Triangulation
Figure 90. Key Executives Interviewed
KEY QUESTIONS ADDRESSED BY THE REPORT
Which companies rank high in the global Autologous Biologics market?
The top companies in the global Autologous Biologics market are Vericel Corporation、BioTime, Inc.、Pharmicell Co..
Related Reports
Autologous Biologics- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Autologous Biologics was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of %from 2026 to 2032.
Published Date: 2026-06-16
Pages: 130
USD 3950.00
(Single User License)
Global Autologous Biologics Market Research Report 2026
The global Autologous Biologics market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Published Date: 2026-04-17
Pages: 115
USD 2900.00
(Single User License)
Global Autologous Biologics Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Autologous Biologics market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-11-02
Pages: 78
USD 4250.00
(Single User License)
Autologous Biologics- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Autologous Biologics was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-01-13
Pages: 97
USD 3950.00
(Single User License)
Global Autologous Biologics Market Research Report 2025
The global market for Autologous Biologics was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published Date: 2025-01-13
Pages: 83
USD 2900.00
(Single User License)
Autologous Biologics- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Autologous Biologics was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of %from 2026 to 2032.
Published: 2026-06-16
Pages: 130
USD 3950.00 (Single User License)Global Autologous Biologics Market Research Report 2026
The global Autologous Biologics market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Published: 2026-04-17
Pages: 115
USD 2900.00 (Single User License)Global Autologous Biologics Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Autologous Biologics market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-11-02
Pages: 78
USD 4250.00 (Single User License)Autologous Biologics- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Autologous Biologics was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-01-13
Pages: 97
USD 3950.00 (Single User License)Global Autologous Biologics Market Research Report 2025
The global market for Autologous Biologics was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published: 2025-01-13
Pages: 83
USD 2900.00 (Single User License)
CHOOSE LICENSE TYPE
USD 4900.00
USD 7350.00
USD 9800.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
WHY THIS REPORT
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now